Podcasts about gastroenterology and hepatology

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Stefan Holubar, MD, MS When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn's disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Benson, MD Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: J. Andy Tau, MD Topical hemostatic agents play a key role in managing complex bleeding cases, but there's a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-impact-of-first-line-treatment-on-subsequent-treatment-options-for-metastatic-escc/33031/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-first-line-regimens-patient-centric-selection-in-metastatic-escc/33030/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-navigating-first-line-treatment-selection-in-metastatic-escc/33029/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/ici-combination-regimens-for-first-line-treatment-of-metastatic-escc/33028/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

Guest: Elisa K. Boden, MD For patients with Crohn's disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it's still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Guest: Elisa K. Boden, MD For many patients with Crohn's disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn's and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Shalini Prasad, PhD Guest: Sriram Muthukumar, PhD Host: Charles Turck, PharmD, BCPS, BCCCP With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.

Guest: Elisa K. Boden, MD For patients with Crohn's disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Elisa K. Boden, MD For many patients with Crohn's disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn's and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it's still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

CME credits: 0.50 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/preparing-the-patient-with-decompensated-cirrhosis-for-liver-transplant-icu-discussions-considerations-and-dialysis/26987/ In patients with cirrhosis and kidney dysfunction who are candidates for liver transplantation, transplant decisions are impacted by kidney function impacting MELD scores. This podcast explores ICU management of these patients, including the use of dialysis, and emphasizes the importance of considering multiple factors such as the etiology of liver disease, presence of chronic kidney disease, and individual patient characteristics. The experts highlight recent changes in transplant criteria, particularly for alcoholic hepatitis patients, and discuss the challenges of managing an increasingly diverse patient population ranging from young alcohol-related liver disease patients to older patients with metabolic-associated liver disease and multiple comorbidities. =

CME credits: 0.50 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/acute-kidney-injury-in-cirrhosis-multidisciplinary-decision-making/26986/ In patients with decompensated cirrhosis and multi-organ failure, intensive care units must coordinate care between hepatologists, transplant surgeons, intensivists, and nephrologists to optimize patient outcomes. This roundtable highlights the importance of well-coordinated processes between floor units and ICU teams, including early response systems and regular multidisciplinary rounds to discuss management strategies and transplant considerations. Different specialists must collaborate effectively to make decisions about various treatments, including terlipressin administration, dialysis initiation, and transplant timing, particularly in challenging cases like alcoholic hepatitis. This activity also covers how teams must carefully balance improving kidney function against maintaining transplant priority scores.=

CME credits: 0.25 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/evaluation-and-management-of-aki-in-cirrhosis-at-the-interface-of-gastroenterology-and-nephrology/26988/ In patients with advanced liver disease, decompensated cirrhosis and portal hypertension can impact kidney function through development of acute kidney injury (AKI). Multiple different etiologies of AKI can be seen in cirrhotic patients, including prerenal AKI, acute tubular injury, and hepatorenal syndrome (HRS), which require different treatment approaches. This podcast will emphasize the importance of multidisciplinary care and use of established protocols in treating these patients, particularly when considering a bridge to liver transplantation, and discuss specific considerations for patients with transjugular intrahepatic portosystemic shunt (TIPS).=

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Recent changes to the American College of Gastroenterology's guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone's Inflammatory Bowel Disease Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD With so many therapeutic options for Crohn's disease and ulcerative colitis, it can be challenging to determine which one best matches your patient's needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic landscape for inflammatory bowel disease.

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/chemotherapy-strategies-for-metastatic-pdac/26435/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-management-of-metastatic-pdac/26434/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-between-anti-pd-1-agents-in-escc-combination-therapies/29790/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-importance-of-pd-l1-testing-shaping-the-future-of-treatment-in-escc/29791/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/effective-monitoring-and-management-of-adverse-effects-in-metastatic-escc/29792/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.25 Valid until: 18-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-masldmash-treating-the-liver-the-disease-and-the-patient-chairs-perspective/24278/ MASLD/MASH is a serious, chronic, progressive disease that will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. The good news is we now have a recently approved liver-directed therapy. Tune in to ensure you know how to effectively identify and treat MASLD/MASH in your patients.=

CME credits: 0.25 Valid until: 17-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-changing-paradigm-of-treating-masldmash-at-the-crossroads-of-hepato-cardiometabolic-care-chairs-perspective/26372/ MASLD/MASH is a serious, chronic, progressive disease that will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Do you know how to effectively treat MASLD/MASH in your patients, and are you familiar with drugs currently in development? Tune in for an overview of the latest data.=

CME credits: 1.50 Valid until: 04-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-and-management-of-mash-more-options-more-decisions/24277/ Join us for a CME online broadcast replay of a live satellite symposium from ACG 2024, where experts discuss MASLD/MASH, a serious disease that is both chronic and progressive. What's most concerning is that MASLD/MASH will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Until recently there was no liver-directed therapy for this disease, and the metabolic benefits of pharmacologic modification of body weight were underappreciated. This activity will also provide practical interactive discussions of cardiometabolic pathophysiologic pathways; early identification and risk stratification; advances in treatment; monitoring for disease progression; and long-term medical management, including the role of incretin agonists.=

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Phil Ayers, PharmD, BCNSP, FMSHP, FASHP When considering multi-chamber bag parenteral nutrition (MCB-PN), there are a variety of factors to consider, including the patients' hemodynamic stability and nutrient needs. After a patient is selected, their whole care team must be aware of common risks and challenges to ensure safe and effective delivery. Dr. Charles Turck is joined by Dr. Phil Ayers to discuss appropriate patient selection based on recent updates to ASPEN guidelines and safety considerations. Dr. Ayers is a Clinical Associate Professor at the University of Mississippi School of Pharmacy and the Chief of Clinical Pharmacy Services in the Department of Pharmacy at Baptist Medical Center in Jackson, MI.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD While neuromodulators are primarily used to treat psychiatric disorders, they can also help normalize symptoms of irritable bowel syndrome by targeting the gut-brain axis. In fact, about half of all patients with IBS have the potential to benefit from neuromodulators. Dr. Douglass Drossman joins Dr. Peter Buch to discuss his research on how various neuromodulators can provide relief for IBS patients. Dr. Drossman is the President of the Drossman Center of Education and Practice of Psychosocial Care and Drossman Consulting as well as a Professor Emeritus of Medicine and Psychiatry at the University of North Carolina School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Steven Maron, MD, MSc Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it's important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient's treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York. References: The Cancer Genome Atlas Network. Nature. 2014;513:202-209. Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283. American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024. Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082. ©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-target-practice-normalization-is-the-new-norm/29110/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/initiating-second-line-therapy-what-when-and-then-what/29111/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-is-risky-business/29109/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-2/29115/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-1/29114/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-an-itchy-patient-behind-those-numbers/29113/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-a-sleepy-patient-behind-those-numbers/29112/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Grady, MD While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kyle Staller, MD, MPH The complexities of gastroparesis can make the disease difficult to diagnose and treat. To help us overcome these challenges, Dr. Kyle Staller joins Dr. Peter Buch to share his preferred strategies for managing patients with gastroparesis. Not only is Dr. Staller an Assistant Professor of Medicine at Harvard University, but he's also the Director of the GI Motility Lab at the Massachusetts General Hospital.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kyle Staller, MD, MPH Join Dr. Peter Buch as he speaks with Dr. Kyle Staller, Director of the Gastrointestinal Motility Laboratory at Mass General and Assistant Professor of Medicine at Harvard Medical School, about uncovering the cause of a patient's bloating and determining how to manage it.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Edward L. Barnes, MD, MPH Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders. Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders. Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brian E. Lacy, MD, PhD About 50 percent of gastrointestinal providers are experiencing some degree of burnout, which can lead to a variety of personal and professional challenges. Joining Dr. Peter Buch to discuss the signs of burnout and what you can do to mitigate them is Dr. Brian Lacy, lead author of the “Burnout in Gastrointestinal Providers” article published in the American Journal of Gastroenterology in 2024.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Eamonn Quigley, MD Small intestinal bacterial overgrowth (SIBO) is often overdiagnosed due to misconceptions about symptoms and inaccurate tests. Join Dr. Peter Buch and Dr. Eamonn Quigley as they explore considerations for knowing when and how to diagnose and treat SIBO. Dr. Quigley is the Chief of Gastroenterology and Hepatology and the Co-Director of the Lynda K. and David M. Underwood Center for Digestive Disorders at Houston Methodist Hospital.

Host: Jennifer Caudle, DO Guest: A. Mark Fendrick, MD Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn the details of this study and how we can incorporate the findings into practice, join Dr. Jennifer Caudle as she speaks with Dr. Mark Fendrick, Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Naga Chalasani, MD It's recommended that if patients with cirrhosis are using acetaminophen long-term, it should be a limited dosage. But should we be avoiding nonsteroidals in patients with decompensation cirrhosis? To walk through the impacts of analgesics in patients with cirrhosis, join Dr. Peter Buch as he speaks with Dr. Naga Chalasani, David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine.